1357576-48-7

1357576-48-7 structure

Name: AZD4320
Chemical Name: AZD4320
CAS Number: 1357576-48-7
Molecular Formula: C₄₅H₄₈ClF₃N₄O₇S₃
Molecular Weight: 945.53
Catalog: Signaling Pathways Apoptosis Bcl-2 Family
Create Date: 2018-06-20 03:47:00
Modify Date: 2024-01-06 22:31:54
AZD4320 is a novel BH3-mimicking dual BCL2/BCLxL inhibitor with IC50s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively.

Name	AZD4320

Description	AZD4320 is a novel BH3-mimicking dual BCL2/BCLxL inhibitor with IC50s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively.
Related Catalog	Signaling Pathways >> Apoptosis >> Bcl-2 Family Research Areas >> Cancer
Target	BCL2:17 nM (IC50, KPUM-UH1 cells) BCLxL:17 nM (IC50, KPUM-UH1 cells)
In Vitro	AZD4320 potently augments the antitumor effect of AZD5153 (Cat. No.: HY-100653A) in double expressing lymphoma (DEL)- and double hit lymphoma (DHL)-derived cell lines in a dose-dependent manner. AZD4320 shows mostly synergistic, and at least additive, growth inhibitory effects on DEL- and DHL derived cell lines, and profoundly increases cells undergoing apoptosis in all three cell lines[1].
Cell Assay	Two DEL-derived cell lines, KPUM-MS3 and KPUM-UH1, and a DHL-derived cell line, STR-428 are used. To examine the combinatory growth inhibitory effects of AZD4320, cells are treated with five concentrations (0.25, 0.5, 1.0, 2.0, 4.0×IC50) for 72 h, and subjected to a modified MTT assay[1].
References	[1]. Takimoto-Shimomura T, et al. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. Invest New Drugs. 2018 Jun 21.